Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment

[Reuters] – Bristol-Myers Squibb said it withdrew its U.S. Bristol-Myers is racing against Merck & Co and AbbVie to try and cut the treatment time by half and avoid side effects from older . . . → Read More: Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces Retirement of Brian Daniels